cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.3569676
title: Burden of illness for super-refractory status epilepticus patients

description: <b>Objective:</b> To provide an estimate of the annual number of super-refractory status epilepticus (SRSE) cases in the United States (US) and to evaluate utilization of hospital resources by these patients. <b>Methods:</b> The Premier Hospital Database was utilized to estimate the number of SRSE cases based on hospital discharges during 2012. Discharges were classified as SRSE cases based on an algorithm using seizure-related International Classification of Diseases-9 (ICD-9) codes, Intensive Care Unit (ICU) length of stay (LOS), and treatment protocols (e.g., benzodiazepines, antiepileptic drugs (AEDs), and ventilator use). Secondary analyses were conducted using more restrictive algorithms for SRSE. <b>Results:</b> A total of 6,325 hospital discharges were classified as SRSE cases from a total of 5,300,000 hospital discharges. Applying a weighting based on hospital characteristics and 2012 US demographics, this projected to an estimated 41,156 cases of SRSE in the US during 2012, an estimated incidence rate of approximately 13/100,000 annually for SRSE in the US. Secondary analyses using stricter SRSE algorithms resulted in estimated incidence rates of approximately 11/100,000 and 8/100,000 annually. The mean LOS for SRSE hospitalizations was 16.5 days (median = 11; interquartile range [IQR] = 6–20), and the mean LOS in ICU was 9.3 days (median = 6; IQR = 3–12). The mean cost of an SRSE hospitalization was $51,247 (median=$33,294; 95% CI=$49,634–$52,861). <b>Limitations:</b> The analysis uses ICD-9 diagnostic codes and claims information, and there are inherent limitations in any methodology based on treatment protocol, which created challenges in distinguishing with complete accuracy between SRSE, RSE, and SE on the basis of care patterns in the database. <b>Conclusion:</b> SRSE is associated with high mortality and morbidity, which place a high burden on healthcare resources. Projections based upon the findings of this study suggest an estimated 25,821 to 41,959 cases of SRSE may occur in the US each year, but more in-depth studies are required.
DOI: 10.7910/dvn/0waeam/ebgwnl
title: gneezy_israel_ultimaumB_viol_exp_dummy.tab

description: :unav
DOI: 10.6084/m9.figshare.3569676.v1
title: Burden of illness for super-refractory status epilepticus patients

description: <b>Objective:</b> To provide an estimate of the annual number of super-refractory status epilepticus (SRSE) cases in the United States (US) and to evaluate utilization of hospital resources by these patients. <b>Methods:</b> The Premier Hospital Database was utilized to estimate the number of SRSE cases based on hospital discharges during 2012. Discharges were classified as SRSE cases based on an algorithm using seizure-related International Classification of Diseases-9 (ICD-9) codes, Intensive Care Unit (ICU) length of stay (LOS), and treatment protocols (e.g., benzodiazepines, antiepileptic drugs (AEDs), and ventilator use). Secondary analyses were conducted using more restrictive algorithms for SRSE. <b>Results:</b> A total of 6,325 hospital discharges were classified as SRSE cases from a total of 5,300,000 hospital discharges. Applying a weighting based on hospital characteristics and 2012 US demographics, this projected to an estimated 41,156 cases of SRSE in the US during 2012, an estimated incidence rate of approximately 13/100,000 annually for SRSE in the US. Secondary analyses using stricter SRSE algorithms resulted in estimated incidence rates of approximately 11/100,000 and 8/100,000 annually. The mean LOS for SRSE hospitalizations was 16.5 days (median = 11; interquartile range [IQR] = 6–20), and the mean LOS in ICU was 9.3 days (median = 6; IQR = 3–12). The mean cost of an SRSE hospitalization was $51,247 (median=$33,294; 95% CI=$49,634–$52,861). <b>Limitations:</b> The analysis uses ICD-9 diagnostic codes and claims information, and there are inherent limitations in any methodology based on treatment protocol, which created challenges in distinguishing with complete accuracy between SRSE, RSE, and SE on the basis of care patterns in the database. <b>Conclusion:</b> SRSE is associated with high mortality and morbidity, which place a high burden on healthcare resources. Projections based upon the findings of this study suggest an estimated 25,821 to 41,959 cases of SRSE may occur in the US each year, but more in-depth studies are required.
DOI: 10.7910/dvn/0waeam/2qswkg
title: grossman_israel_knowledgepolitics_std_viol_exp_dummy.tab

description: :unav
DOI: 10.7910/dvn/0waeam/swqxho
title: bauer_georgia_groupparticipation_std_viol_exp_dummy.tab

description: :unav
DOI: 10.7910/dvn/0waeam/h6hm7z
title: bateson_latin_america_knowledgepolitics_std_viol_exp_personal_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/mqwvcu
title: grosjean_europe_prosocial_indexA_viol_exp_std.tab

description: :unav
DOI: 10.6084/m9.figshare.3569658
title: Supplementary Material for: Evaluation of Cardiovascular Risk Factors, Haematological and Biochemical Parameters, and Serum Endocan Levels in Patients with Lichen Planus

description: <strong><em>Background and Objective:</em></strong> The current study aimed to evaluate cardiovascular risk factors, haematological and biochemical parameters, and serum endocan concentrations in lichen planus (LP) patients. <b><i>Methods:</i></b> This study was conducted with 86 cases, including 43 LP patients and 43 healthy controls. Cardiovascular risk factors, haematological and biochemical parameters, and endocan levels were evaluated. <b><i>Results:</i></b> The serum endocan concentrations of LP patients were not significantly different from those of the healthy controls (p &gt; 0.05). There were no significant differences in the serum endocan levels according to classification by cardiovascular risk factors and smoking history (p &gt; 0.05). In the LP group, white blood cell count, platelet distribution width and monocyte count/high-density lipoprotein cholesterol ratios were significantly higher when compared to the healthy controls (p &lt; 0.05). The LP group had a lower mean platelet volume than the healthy controls (p &lt; 0.05). <b><i>Conclusions:</i></b> Serum endocan levels did not change significantly in patients with LP, and there were significant differences in haematological and biochemical parameters.
DOI: 10.7910/dvn/0waeam/hy5oxd
title: standardized_personal_forest_trust_ingroup_RE.R

description: :unav
DOI: 10.7910/dvn/0waeam/cdrhe6
title: bellows_sierra_leone_prosocial_indexM_viol_exp_community_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/s4qnon
title: bateson_us_canada_voting_std_viol_exp_personal_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/yjgzdw
title: forest_plot_trust_ingroup_FE.pdf

description: :unav
DOI: 10.6084/m9.figshare.3569649
title: Supplementary Material for: Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study

description: <strong><em>Background:</em></strong> Breast cancer guidelines suggest the use of gene expression profiles (GEPs) in estrogen receptor-positive (ER+) breast cancer patients in whom controversy exists regarding adjuvant chemotherapy benefit based on traditional prognostic factors alone. We evaluated the current use of GEPs in these patients in the Netherlands. <b><i>Patients and Methods:</i></b> Primary breast cancer patients treated between January 1, 2011 and December 31, 2014 and eligible for GEP use according to the Dutch national breast cancer guideline were identified in the Netherlands Cancer Registry: ER+ patients &lt;70 years with grade 1 tumors &gt;2 cm or grade 2 tumors 1-2 cm without overt lymph node metastases (pN0-Nmi). Mixed-effect logistic regression analysis was performed to associate characteristics of patients, tumors and hospitals with GEP use. <b><i>Results:</i></b> GEPs were increasingly deployed: 12% of eligible patients received a GEP in 2011 versus 46% in 2014. Lobular versus ductal morphology (OR 0.58, 95% CI 0.47-0.72), pN1mi status (versus pN0, OR 0.52, 95% CI 0.40-0.68), and tumor size (&gt;3 cm vs. &gt;2 cm, OR 0.33, 95% CI 0.14-0.88) were inversely associated with GEP use. High socioeconomic status (SES) (OR 1.32, 95% CI 1.06-1.64) and younger age (OR 0.96/year increasing age, 95% CI 0.95-0.96) were positively associated with GEP use. GEP use per hospital did vary, but no predefined institutional factors remained independently associated with GEP use. <b><i>Conclusion:</i></b> GEP use increased over time and was influenced by patient- and tumor-associated factors as well as by SES.
DOI: 10.7910/dvn/0waeam/3t5amr
title: bauer_sierra_leone_voting_std_viol_exp_dummy.tab

description: :unav
DOI: 10.7910/dvn/0waeam/fsa9xa
title: annan_ugandafemales_trustall_std_viol_exp_community_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/4kold9
title: bellows_sierra_leone_knowledgepolitics_std_viol_exp_dummy.tab

description: :unav
DOI: 10.7910/dvn/0waeam/6rpemu
title: forest_plot_community_FE.pdf

description: :unav
DOI: 10.7910/dvn/0waeam/fzxl0t
title: cecchi_sierra_leone_dictator_stdoutgroup_viol_exp_personal_std.tab

description: :unav
DOI: 10.6084/m9.figshare.3569643
title: Supplementary Material for: Glucocorticoid Receptor Gene Variants and Neonatal Outcome in Very-Low-Birth-Weight Preterm Infants

description: <strong><em>Background:</em></strong> Induction of lung maturation by prenatal steroid treatment has become the standard of care for pregnant women at risk for preterm birth. In addition to the beneficial effects on lung maturation, prenatal steroids have been shown to reduce the incidence of neonatal death, necrotizing enterocolitis, sepsis, and intraventricular hemorrhage. However, little is known about the role of interindividual differences in corticoid sensitivity arising from polymorphisms in the glucocorticoid receptor <i>(GR)</i> gene. <b><i>Objectives:</i></b> To assess the impact of <i>GR</i> polymorphisms <i>N363S</i> (rs56149945), <i>R23K</i> (rs6190), and <i>BclI</i> (rs41423247) on neonatal outcome. <b><i>Methods:</i></b> The <i>GR</i> polymorphisms <i>N363S, R23K,</i> and <i>BclI</i> were examined in 10,490 very-low-birth-weight (VLBW) preterm infants from 49 German tertiary level neonatal units (German Neonatal Network, GNN) with respect to neonatal outcome. <b><i>Results:</i></b> Infants carrying the <i>BclI</i> genotype were at higher risk to develop bronchopulmonary dysplasia (BPD) (OR 1.12 per <i>BclI</i> allele, 95% CI: 1.02-1.23, p = 0.013) in a logistic regression model adjusted for gestational age, mechanical ventilation, and small for gestational age status. A similar relative risk was seen in the children (89.4%) who received antenatal betamethasone treatment (OR 1.16, 95% CI: 1.05-1.27, p = 0.003), whereas no such effect was detectable in infants without antenatal steroids. <i>N363S</i> and <i>R23K</i> did not show any stable association with neonatal outcome parameters. <b><i>Conclusion:</i></b> Except for a slightly higher risk of BPD in carriers of the <i>GR</i><i>BclI</i> variant, the <i>GR</i> gene polymorphisms <i>BclI, N363S,</i> and <i>R23K</i> did not affect neonatal outcome parameters in this large multicenter cohort of VLBW preterm infants.
DOI: 10.7910/dvn/0waeam/ykxwa4
title: bateson_europe_knowledgepolitics_std_viol_exp_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/q7tver
title: bauer_uganda_gamesingroup_trust_tot_viol_exp_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/fpdel2
title: gilligan_nepal_cooperate_std_viol_exp_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/5sg9p3
title: cassar_tajikistan_voting_std_viol_exp_std.tab

description: :unav
DOI: 10.6084/m9.figshare.3569637
title: Supplementary Material for: Twelve-Month and Lifetime Prevalence of Mental Disorders in Cancer Patients

description: <strong><em>Background:</em></strong> Psychological problems are common in cancer patients. For the purpose of planning psycho-oncological interventions and services tailored to the specific needs of different cancer patient populations, it is necessary to know to what extent psychological problems meet the criteria of mental disorders. The purpose of this study was to estimate the 12-month and lifetime prevalence rates of mental disorders in cancer patients. <b><i>Methods:</i></b> A representative sample of patients with different tumour entities and tumour stages (n = 2,141) in outpatient, inpatient and rehabilitation settings underwent the standardized computer-assisted Composite International Diagnostic Interview for mental disorders adapted for cancer patients (CIDI-O). <b><i>Results:</i></b> The overall 12-month prevalence for any mental disorder was 39.4% (95% CI: 37.3-41.5), that for anxiety disorders was 15.8% (95% CI: 14.4-17.4), 12.5% (95% CI: 11.3-14.0) for mood disorders, 9.5% (95% CI: 8.3-10.9) for somatoform disorders, 7.3% (95% CI: 6.2-8.5) for nicotine dependence, 3.7% (95% CI: 3.0-4.6) for disorders due to general medical condition, and 1.1% (95% CI: 0.7-1.6) for alcohol abuse or dependence. Lifetime prevalence for any mental disorder was 56.3% (95% CI 54.1-58.6), that for anxiety disorders was 24.1% (95% CI: 22.3-25.9), 20.5% (95% CI: 18.9-22.3) for mood disorders, 19.9% (95% CI: 18.3-21.7) for somatoform disorders, 18.2% (95% CI: 16.6-20.0) for nicotine dependence, 6.4% (95% CI: 5.4-7.6) for alcohol abuse or dependence, 4.6% (95% CI: 3.8-5.6) for disorders due to general medical condition, and 0.2% (95% CI: 0.1-0.6) for eating disorders. <b><i>Conclusions:</i></b> Mental disorders are highly prevalent in cancer patients, indicating the need for provision of continuous psycho-oncological support from inpatient to outpatient care, leading to an appropriate allocation of direct personnel and other resources.
DOI: 10.7910/dvn/0waeam/tqaitg
title: bauer_georgia_gamesingroupegalitarian_std_viol_exp_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/s9lpks
title: annan_ugandafemales_knowledgepolitics_std_viol_exp_community_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/qvilqr
title: annan_ugandafemales_groupparticipation_std_viol_exp_community_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/cr9cdu
title: gilligan_nepal_sharereturn_std_viol_exp_community_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/dkrkns
title: binary_forest_community_FE.R

description: :unav
DOI: 10.7910/dvn/0waeam/a8vsnq
title: README.txt

description: :unav
DOI: 10.7910/dvn/0waeam/sqy0tg
title: bauer_uganda_gamesingroup_trust_tot_viol_exp_community_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/yhw0ng
title: bauer_sierra_leone_communityparticipation_std_viol_exp_community_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/ichlte
title: deluca_uganda_2015b_voting_std_viol_exp_community_std.tab

description: :unav
DOI: 10.6084/m9.figshare.3569469
title: Tectonic geomorphology of the Fox Peak and Forest Creek Faults, South Canterbury, New Zealand: slip rates, segmentation and earthquake magnitudes

description: The Fox Peak and Forest Creek Faults in South Canterbury show evidence for segmentation based on the surface expression of late Quaternary faulting. Slip rates were calculated at over 100 sites along the Fox Peak Fault from (a) global positioning system (GPS) and total station fault scarp profiles; (b) field measurements of fault geometry and kinematics; and (c) age data from infrared stimulated luminescence, Schmidt hammer exposure-age dating and regional map correlations. Near the centre of fault segments, maximum slip rates for the Fox Peak Fault reach c. 1.6–1.7 mm yr<sup>−1</sup>, whereas an average slip rate of c. 1–1.5 mm yr<sup>−1</sup> summed across the Forest Creek and Fox Peak Faults falls below rates derived by geodetic models. The geomorphology and single event displacements suggest segment-breaching ruptures of the Fox Peak Fault during late Quaternary earthquakes with moment magnitudes (<i>M</i><sub>W</sub>) of 7.0–7.2. This study highlights the role that evaluations of landscape evolution in reverse faulting regimes can play in assessing seismic hazard.
DOI: 10.6084/m9.figshare.3569469.v1
title: Tectonic geomorphology of the Fox Peak and Forest Creek Faults, South Canterbury, New Zealand: slip rates, segmentation and earthquake magnitudes

description: The Fox Peak and Forest Creek Faults in South Canterbury show evidence for segmentation based on the surface expression of late Quaternary faulting. Slip rates were calculated at over 100 sites along the Fox Peak Fault from (a) global positioning system (GPS) and total station fault scarp profiles; (b) field measurements of fault geometry and kinematics; and (c) age data from infrared stimulated luminescence, Schmidt hammer exposure-age dating and regional map correlations. Near the centre of fault segments, maximum slip rates for the Fox Peak Fault reach c. 1.6–1.7 mm yr<sup>−1</sup>, whereas an average slip rate of c. 1–1.5 mm yr<sup>−1</sup> summed across the Forest Creek and Fox Peak Faults falls below rates derived by geodetic models. The geomorphology and single event displacements suggest segment-breaching ruptures of the Fox Peak Fault during late Quaternary earthquakes with moment magnitudes (<i>M</i><sub>W</sub>) of 7.0–7.2. This study highlights the role that evaluations of landscape evolution in reverse faulting regimes can play in assessing seismic hazard.
DOI: 10.6084/m9.figshare.3569466
title: PACIENTES COM DOR NEUROPÁTICA HANSÊNICA: UMA ABORDAGEM CLÍNICA E NEUROFISIOLÓGICA.

description: Leprosy is an infectious diseases of dermatologic involvement with the highest incidence in the world. Many patients develop permanent peripheral nerve injury as a result of late diagnosis and/or poor follow up, which can progress to chronic pain, at times incapacitating and refractory
DOI: 10.7910/dvn/0waeam/fcpcqc
title: forest_plot_games_all_FE.pdf

description: :unav
DOI: 10.6084/m9.figshare.3569466.v1
title: PACIENTES COM DOR NEUROPÁTICA HANSÊNICA: UMA ABORDAGEM CLÍNICA E NEUROFISIOLÓGICA.

description: Leprosy is an infectious diseases of dermatologic involvement with the highest incidence in the world. Many patients develop permanent peripheral nerve injury as a result of late diagnosis and/or poor follow up, which can progress to chronic pain, at times incapacitating and refractory
DOI: 10.7910/dvn/0waeam/vjppjw
title: forest_plot_trust_outgroup_FE.pdf

description: :unav
DOI: 10.7910/dvn/0waeam/aozcu8
title: binary_forest_games_all_RE.R

description: :unav
DOI: 10.7910/dvn/0waeam/vw45eq
title: bateson_africa_voting_std_viol_exp_std.tab

description: :unav
DOI: 10.6084/m9.figshare.3569454
title: Evaluation of the antihyperalgesic effect of tapentadol in two human evoked pain models – the TapCapMentho pilot trial

description: <b>Objective</b>: Tapentadol is effective in the treatment of neuropathic and nociceptive pain and in acute and chronic pain conditions; two mechanisms combining opioid µ-receptor agonism and noradrenergic reuptake inhibition underlie its analgesic effect. <b>Research design and methods</b>: With this single-center, placebo-controlled, double-blind, cross-over pilot-study, we investigated the antihyperalgesic effect of a single oral dose of 100 mg immediate-release tapentadol on thermal and mechanical hyperalgesia in two human models (i.e. 0.6 % topical capsaicin and 40% topical menthol) of evoked neuropathic pain signs in healthy volunteers. <b>Results</b>: No significant differences regarding experimentally induced heat or cold and mechanical (pinprick) hyperalgesia, as assessed by quantitative sensory testing, could be observed between a single dose of drug and placebo (thermal pain thresholds p&gt;0.4, mechanical pain sensitivity p&gt;0.1). Only few mild side effects of tapentadol were reported. <b>Conclusions</b>: The discrepancy between pain models using healthy volunteers and drug trials under real acute and chronic pain conditions in patients as well as methodological aspects may have contributed to this result. The impact of these findings questions the general use of pain models as predictors for early decision making during drug development. The study was registered in ClinicalTrials.gov (NCT01615510).
DOI: 10.6084/m9.figshare.3569454.v1
title: Evaluation of the antihyperalgesic effect of tapentadol in two human evoked pain models – the TapCapMentho pilot trial

description: <b>Objective</b>: Tapentadol is effective in the treatment of neuropathic and nociceptive pain and in acute and chronic pain conditions; two mechanisms combining opioid µ-receptor agonism and noradrenergic reuptake inhibition underlie its analgesic effect. <b>Research design and methods</b>: With this single-center, placebo-controlled, double-blind, cross-over pilot-study, we investigated the antihyperalgesic effect of a single oral dose of 100 mg immediate-release tapentadol on thermal and mechanical hyperalgesia in two human models (i.e. 0.6 % topical capsaicin and 40% topical menthol) of evoked neuropathic pain signs in healthy volunteers. <b>Results</b>: No significant differences regarding experimentally induced heat or cold and mechanical (pinprick) hyperalgesia, as assessed by quantitative sensory testing, could be observed between a single dose of drug and placebo (thermal pain thresholds p&gt;0.4, mechanical pain sensitivity p&gt;0.1). Only few mild side effects of tapentadol were reported. <b>Conclusions</b>: The discrepancy between pain models using healthy volunteers and drug trials under real acute and chronic pain conditions in patients as well as methodological aspects may have contributed to this result. The impact of these findings questions the general use of pain models as predictors for early decision making during drug development. The study was registered in ClinicalTrials.gov (NCT01615510).
DOI: 10.7910/dvn/0waeam/tb336s
title: bateson_africa_communityparticipation_std_viol_exp_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/2pingy
title: voors_burundi12_prosocial_indexM_viol_exp_std.tab

description: :unav
DOI: 10.7910/dvn/0waeam/p1y6n4
title: standardized_personal_forest_knowledge_politics_RE.R

description: :unav
DOI: 10.7910/dvn/0waeam/bxzlss
title: bauer_uganda_communityparticipation_std_viol_exp_dummy.tab

description: :unav
DOI: 10.7910/dvn/0waeam/lpan9s
title: .Rapp.history

description: :unav